![]() ![]() The following information should be read in conjunction with the financial statements and management's discussion and analysis, which are available under Novamind's SEDAR profile at Supplemental Disclosure for Circular Novamind confirms that the management information circular dated (the "Circular"), form of proxy and other materials with respect to the Company's Arrangement with Numinus have been mailed to Novamind Shareholders of record as of May 2, 2022. The following table presents selected financial information from Novamind's reviewed condensed interim financial statements for the three and nine months ended March 31, 2022. ![]() Closed a $5,000,000 private placement with an institutional investor.Total working capital of $3,928,642 to fund operations.Total revenue $3,227,352, +32% over the previous quarter.A phase II randomized clinical study for the acute treatment of social anxiety disorder, sponsored by Bionomics.A phase II clinical trial investigating an antidepressant medication for adults with major depressive disorder and PTSD, sponsored by Alto Neuroscience.A phase I clinical trial investigating the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy for the treatment of adults with opioid use disorder.A phase II clinical trial investigating ketamine-assisted psychotherapy for adults with life-threatening illnesses, sponsored by the Ketamine Research Foundation.A phase II clinical trial investigating psilocybin for major depressive disorder, sponsored by the Usona Institute.A phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults, sponsored by MindMed. ![]() Contracted to provide clinical research services for the following clinical trials:.Novamind's strategic partner, Bienstar Wellness Corp., signed a letter of intent to acquire BRC Saude Mental E Terapias Assistidas Ltda., a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil.Launched Groups by Novamind, an expansion of the Company's clinical care model focused on increasing patient access to mental health treatments.Opened the Company's eighth integrative psychiatry clinic, located in Phoenix, Arizona.Closed the acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.A special meeting of the Company's shareholders will be held on June 8, 2022, to approve the proposed acquisition of Novamind by Numinus.The Arrangement values Novamind at $26.2 million on a fully diluted in-the-money basis, representing a premium of 51% to Novamind's 20-day volume-weighted average price on the Canadian Securities Exchange as of April 8, 2022.Pending shareholder approval, holders of Novamind common shares ("Novamind Shareholders") will receive 0.84 of a common share of Numinus for each Novamind share held.The Company entered into a definitive arrangement agreement (the "Arrangement") pursuant to which Numinus Wellness ("Numinus"), will acquire Novamind in an all-share transaction.With the anticipated shareholder approval of the acquisition of Novamind by Numinus in June, the Company is well-positioned to continue this record growth in pursuit of its mission to responsibly reintroduce psychedelic therapy to mental healthcare."įiscal Q3 2022 Operating Highlights and Subsequent Events Growth was driven by our recent expansion to Arizona in addition to the continued progress of our Utah operations. ![]() Novamind CEO, Yaron Conforti, commented, "Once again, we're pleased to report record-high revenue this quarter. All results are reported under International Financial Reporting Standards ("IFRS") and in Canadian dollars, unless otherwise specified. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, reported its financial results for the three and nine months ended Ma("Fiscal Q3 2022"). TORONTO, ON / ACCESSWIRE / / Novamind Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |